Gubra
303 DKK -0.33%HC Andersen Capital receives payment from Gubra for a DigitalIR/Corporate Visibility agreement. See disclaimer.
12 investors are following this company
Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They mainly conduct research and development in the field of metabolic and fibrotic diseases. The company's product portfolio includes several brands and pharmaceuticals, and operations are conducted on a global level, with the largest presence in North America and the Nordics. The head office is located in Hørsholm, Denmark.
Revenue
205.01M
EBIT %
-23.25 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
GUBRA
Daily low / high price
299 / 308
DKK
Market cap
4.95B DKK
Turnover
4.02M DKK
Volume
13K
Latest research
Latest videos
Financial calendar
Interim report
23.08.2024
ShowingAll content types
Gubra unveils UCN2 as novel anti-obesity drug candidate for healthy weight loss
Gubra – Hvordan er 2024 startet?
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools